Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Kalaris Therapeutics Inc. (KLRS) had Return on Tangible Equity of -12.69% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-10.00M |
|
-- |
|
-- |
|
$10.80M |
|
$-10.80M |
|
$0.80M |
|
$-10.00M |
|
$-10.00M |
|
$-10.00M |
|
$-10.00M |
|
$-10.00M |
|
$-10.00M |
|
$-10.80M |
|
$-11.11M |
|
15.27M |
|
15.27M |
|
$0.92 |
|
$0.92 |
|
| Balance Sheet Financials | |
$118.81M |
|
-- |
|
$2.93M |
|
$121.74M |
|
$9.71M |
|
-- |
|
$33.21M |
|
$42.92M |
|
$78.81M |
|
$78.81M |
|
$78.81M |
|
22.90M |
|
| Cash Flow Statement Financials | |
$-38.37M |
|
$-19.72M |
|
$155.01M |
|
$1.64M |
|
$98.55M |
|
$96.91M |
|
$1.94M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.23 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-38.57M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.69% |
|
|
Return on Tangible Equity |
-12.69% |
-8.21% |
|
-12.69% |
|
$3.44 |
|
$-2.53 |
|
$-2.51 |
|